Collegium completes Ironshore acquisition; discloses Ironshore's $49.8M net loss for 2023 and $67.4M for H1 2024

COLLEGIUM PHARMACEUTICAL, INC

Acquisition closed Sept 3, 2024; Ironshore's JORNAY PM (ADHD) product revenue $78.6M in 2023, $43.8M in H1 2024.
Ironshore total assets $84.7M, total liabilities $442.3M, shareholders' deficit $(357.6)M at June 30, 2024.
Ironshore notes payable (current + non-current) $149.8M at June 30, 2024; asset-backed lending $12.6M.
Deferred royalty obligation $123.5M at June 30, 2024; warrant liability $8.3M; derivative liability $36.0M.
Ironshore's net loss $(49.8)M in 2023 and $(67.4)M in H1 2024, with operating losses since inception.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.